[
    [
        {
            "time": "2018-09-24",
            "original_text": "Cramer advises staying away from animal health play Elanco at these levels",
            "features": {
                "keywords": [
                    "Cramer",
                    "Elanco",
                    "animal health",
                    "advises",
                    "stay away"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "animal health"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Cramer advises staying away from animal health play Elanco at these levels",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-03-22",
            "original_text": "J&J's Esketamine Fails to Meet Endpoint in Phase III Study",
            "features": {
                "keywords": [
                    "J&J",
                    "Esketamine",
                    "Phase III",
                    "fails"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "J&J's Esketamine Fails to Meet Endpoint in Phase III Study",
                "Correlation": 2,
                "Sentiment": 2,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-09-25",
            "original_text": "Newly Public Elanco Seeks to Innovate With Offering Proceeds",
            "features": {
                "keywords": [
                    "Elanco",
                    "public",
                    "innovate",
                    "offering proceeds"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "animal health"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Newly Public Elanco Seeks to Innovate With Offering Proceeds",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-09-21",
            "original_text": "Elanco Animal Health Incorporated Announces IPO Closing",
            "features": {
                "keywords": [
                    "Elanco",
                    "IPO",
                    "closing"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "animal health"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Elanco Animal Health Incorporated Announces IPO Closing",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-09-20",
            "original_text": "Eli Lilly spin-off Elanco creating ‘disruptive’ opportunity in animal health: CEO",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Elanco",
                    "spin-off",
                    "disruptive",
                    "opportunity",
                    "animal health"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "animal health"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Eli Lilly spin-off Elanco creating ‘disruptive’ opportunity in animal health: CEO",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-09-27",
            "original_text": "Lilly's Migraine Drug Emgality Wins Positive CHMP Opinion",
            "features": {
                "keywords": [
                    "Lilly",
                    "Migraine",
                    "Drug",
                    "Emgality",
                    "CHMP",
                    "Wins"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Lilly's Migraine Drug Emgality Wins Positive CHMP Opinion",
                "Correlation": 3,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-09-26",
            "original_text": "AstraZeneca's Diabetes Treatment Reduces Cardiovascular Risk",
            "features": {
                "keywords": [
                    "AstraZeneca",
                    "Diabetes",
                    "Treatment",
                    "Cardiovascular",
                    "Risk",
                    "Reduces"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AstraZeneca's Diabetes Treatment Reduces Cardiovascular Risk",
                "Correlation": 1,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 2,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-09-28",
            "original_text": "Elanco shares rally after successful IPO",
            "features": {
                "keywords": [
                    "Elanco",
                    "shares",
                    "rally",
                    "successful",
                    "IPO"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "animal health"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Elanco shares rally after successful IPO",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-09-29",
            "original_text": "Elanco Announces Full Exercise of Additional Stock, Sets Date for Q3 Earnings",
            "features": {
                "keywords": [
                    "Elanco",
                    "Full Exercise",
                    "Additional Stock",
                    "Q3 Earnings"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "animal health"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Elanco Announces Full Exercise of Additional Stock, Sets Date for Q3 Earnings",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        }
    ]
]